Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Open Access
- 1 March 2021
- journal article
- review article
- Published by Springer Nature in Molecular Systems Biology
- Vol. 17 (3) , e10116
Abstract
Broad‐spectrum antibiotics target multiple gram‐positive and gram‐negative bacteria, and can collaterally damage the gut microbiota. Yet, our knowledge of the extent of damage, the antibiotic activity spectra, and the resistance mechanisms of gut microbes is sparse. This limits our ability to mitigate microbiome‐facilitated spread of antibiotic resistance. In addition to antibiotics, non‐antibiotic drugs affect the human microbiome, as shown by metagenomics as well as in vitro studies. Microbiome–drug interactions are bidirectional, as microbes can also modulate drugs. Chemical modifications of antibiotics mostly function as antimicrobial resistance mechanisms, while metabolism of non‐antibiotics can also change the drugs’ pharmacodynamic, pharmacokinetic, and toxic properties. Recent studies have started to unravel the extensive capacity of gut microbes to metabolize drugs, the mechanisms, and the relevance of such events for drug treatment. These findings raise the question whether and to which degree these reciprocal drug–microbiome interactions will differ across individuals, and how to take them into account in drug discovery and precision medicine. This review describes recent developments in the field and discusses future study areas that will benefit from systems biology approaches to better understand the mechanistic role of the human gut microbiota in drug actions.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (MA 8164/1‐1)
- Deutsche Forschungsgemeinschaft (EXE 2124)
- Daimler und Benz Stiftung
- Medical Research Council (MC_UU_00025/11)
This publication has 160 references indexed in Scilit:
- Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine MetabolismCell, 2013
- Antibiotics in early life alter the murine colonic microbiome and adiposityNature, 2012
- Trends in the exploitation of novel drug targetsNature Reviews Drug Discovery, 2011
- Human Disease Models in Drosophila melanogaster and the Role of the Fly in Therapeutic Drug DiscoveryPharmacological Reviews, 2011
- Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic miceProceedings of the National Academy of Sciences, 2011
- Shifting the balance: antibiotic effects on host–microbiota mutualismNature Reviews Microbiology, 2011
- Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial EnzymeScience, 2010
- Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolismProceedings of the National Academy of Sciences, 2009
- Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic TherapyNew England Journal of Medicine, 1981
- IS p-AMINOBENZENESULPHONAMIDE THE ACTIVE AGENT IN PRONTOSIL THERAPY ?The Lancet, 1937